GlassScriptPhysician profile
Cordell L Yoder
NPI 1003894619
$1,414.64
in general payments reported to CMS, 2019-2025
20 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $230 · 2021: $52.11 · 2022: $102 · 2023: $116 · 2024: $323 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $374.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $151.31 | 2020-2025 | |
| Glaxosmithkline, LLC. | $143.58 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Ironshore Pharmaceuticals INC. | $107.73 | 2019-2024 | |
| Lilly USA, LLC | $86.91 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi Pasteur INC. | $78.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $67.71 | 2019-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Seqirus USA INC | $49.81 | 2022-2024 | Fluad Quadrivalent, Flucelvax Quadrivalent, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $47.92 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $43.51 | 2021-2025 | Qelbree |
| Exact Sciences Corporation | $40.62 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $38.42 | 2023-2025 | Dexcom G6 Transmitter |
| Cranial Technologies, INC | $31.62 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $29.59 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $26.39 | 2024 | Sotyktu |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.11 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $18.50 | 2024 | Breztri |
| Abbott Laboratories | $16.35 | 2024 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $15.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cordell Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.